Tumor-Associated Galectin-3 Modulates the Function of Tumor-Reactive T Cells
Open Access
- 28 August 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 68 (17), 7228-7236
- https://doi.org/10.1158/0008-5472.can-08-1245
Abstract
T cells play an important role in cancer immunosurveillance and tumor destruction. However, tumor cells alter immune responses by modulating immune cells through antigen stimulation and immunoregulatory cytokines. A better understanding of the interplay between tumor cells and T cells might provide new strategies to enhance antitumor immunity. Through an antigen-screening approach using colorectal tumor–reactive T cells, we identified an HLA-DR11–restricted T-cell epitope encoded by KIAA0040 as well as MHC-unrestricted human galectin-3 (Gal-3) expressed by tumor cells. Although the biological function of KIAA0040 remains to be determined, we found that Gal-3 functioned as an immune regulator for direct T-cell activation and function. T-cell activation induced by Gal-3 resulted in T-cell apoptosis. We showed that a high level of expression of Gal-3 promoted tumor growth in vitro and in vivo. Using a mouse tumor model, we showed that delivery of high doses of Gal-3 inhibited tumor-reactive T cells and promoted tumor growth in mice receiving tumor-reactive CD8+ T cells. These findings suggest that Gal-3 may function as an immune regulator to inhibit T-cell immune responses and promote tumor growth, thus providing a new mechanism for tumor immune tolerance. [Cancer Res 2008;68(17):7228–36]Other Versions
This publication has 49 references indexed in Scilit:
- Galectin-1 Suppresses Autoimmune Retinal Disease by Promoting Concomitant Th2- and T Regulatory-Mediated Anti-Inflammatory ResponsesThe Journal of Immunology, 2006
- Immunosuppressive networks in the tumour environment and their therapeutic relevanceNature Reviews Cancer, 2005
- Identification of a Mutated Fibronectin As a Tumor Antigen Recognized by CD4+T CellsThe Journal of Experimental Medicine, 2002
- Progress in the development of immunotherapy for the treatment of patients with cancerJournal of Internal Medicine, 2001
- Galectin-3 Protects Human Breast Carcinoma Cells against Nitric Oxide-Induced Apoptosis: Implication of Galectin-3 Function during MetastasisThe American Journal of Pathology, 2001
- Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic proceduresZeitschrift für Krebsforschung und Klinische Onkologie, 2001
- CD4+T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody productionProceedings of the National Academy of Sciences of the United States of America, 2001
- Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells.2001
- Concentrations of galectin-3 in the sera of normal controls and cancer patients.2000
- Human tumor antigens: implications for cancer vaccine developmentJournal of Molecular Medicine, 1999